Bupivacaine inhibits the malignant biological behavior of oral squamous cell carcinoma cells by inhibiting the activation of ERK1/2 and STAT3

BACKGROUND: Oral squamous cell carcinoma (OSCC) is an aggressive malignant tumor. Bupivacaine (Bupi), a local anesthetic drug, has been shown to display anti-tumor activity against a variety of tumors. METHODS: We selected OSCC CAL-27 cells as the in vitro model. Cell toxicity, proliferation, apopto...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zhongchao, Zhang, Jie, Wen, Yongmei, Wang, Pin, Fan, Liyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184410/
https://www.ncbi.nlm.nih.gov/pubmed/34164473
http://dx.doi.org/10.21037/atm-21-1414

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184410/
https://www.ncbi.nlm.nih.gov/pubmed/34164473
http://dx.doi.org/10.21037/atm-21-1414

Ejemplares similares